Active Ingredient History

  • Now
Romidepsin, also known as Istodax, is an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs). Romidepsin is a natural product obtained from the bacterium Chromobacterium violaceum, and works by blocking enzymes known as histone deacetylases, thus inducing apoptosis. It is sometimes referred to as depsipeptide, after the class of molecules to which it belongs. Romidepsin is branded and owned by Gloucester Pharmaceuticals, now a part of Celgene.   Wikipedia

  • SMILES: C\C=C\1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
  • Mol. Mass: 540.71
  • ALogP: 1.43
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$1031.9100 - $1332.4417
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

astella pharma brand of romidepsin | chromadax | chromodax | depsipeptide | fk228 | fk-228 | fr901228 | fr 901228 | fr-901228 | istodax | l-valine, n-(3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-d-valyl-d-cysteinyl-(z)-2,3-didehydro-2-aminobutanoyl-, xi-lactone, cyclic (1-2)-disulfide, (s-(e))- | romidepsin


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue